WO2010130260A3 - Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide - Google Patents

Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide Download PDF

Info

Publication number
WO2010130260A3
WO2010130260A3 PCT/DK2010/050101 DK2010050101W WO2010130260A3 WO 2010130260 A3 WO2010130260 A3 WO 2010130260A3 DK 2010050101 W DK2010050101 W DK 2010050101W WO 2010130260 A3 WO2010130260 A3 WO 2010130260A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl
morpholin
phenyl
butyramide
stable forms
Prior art date
Application number
PCT/DK2010/050101
Other languages
English (en)
Other versions
WO2010130260A9 (fr
WO2010130260A2 (fr
Inventor
Svend Treppendahl
Karin Liltorp
Heidi Lopez De Diego
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010130260(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SG2011082492A priority Critical patent/SG175968A1/en
Priority to EA201171381A priority patent/EA201171381A1/ru
Priority to JP2012510116A priority patent/JP2012526152A/ja
Priority to CN2010800321765A priority patent/CN102459208A/zh
Priority to CA2761383A priority patent/CA2761383A1/fr
Priority to MX2011011885A priority patent/MX2011011885A/es
Priority to NZ596738A priority patent/NZ596738A/xx
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to MA34435A priority patent/MA33351B1/fr
Priority to BRPI1013930A priority patent/BRPI1013930A2/pt
Priority to EP10719726A priority patent/EP2430008A2/fr
Priority to AU2010246724A priority patent/AU2010246724B2/en
Publication of WO2010130260A2 publication Critical patent/WO2010130260A2/fr
Publication of WO2010130260A3 publication Critical patent/WO2010130260A3/fr
Priority to IL216148A priority patent/IL216148A0/en
Priority to ZA2011/08112A priority patent/ZA201108112B/en
Priority to TNP2011000557A priority patent/TN2011000557A1/en
Publication of WO2010130260A9 publication Critical patent/WO2010130260A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'invention porte sur des formes polymorphes du N-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide ainsi qu'un procédé pour la fabrication dudit composé.
PCT/DK2010/050101 2009-05-11 2010-05-11 Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide WO2010130260A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MA34435A MA33351B1 (fr) 2009-05-11 2010-05-11 Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide
BRPI1013930A BRPI1013930A2 (pt) 2009-05-11 2010-05-11 "composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, processo para a fabricação de um composto."
EA201171381A EA201171381A1 (ru) 2009-05-11 2010-05-11 Стабильные формы n-(2,6-диметил-4-морфолин-4-илфенил)-3,3-диметилбутирамида
EP10719726A EP2430008A2 (fr) 2009-05-11 2010-05-11 Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide
CA2761383A CA2761383A1 (fr) 2009-05-11 2010-05-11 Formes stables du n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutyramide
MX2011011885A MX2011011885A (es) 2009-05-11 2010-05-11 Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimet il-butiramida.
NZ596738A NZ596738A (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
SG2011082492A SG175968A1 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
AU2010246724A AU2010246724B2 (en) 2009-05-11 2010-05-11 Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramide
JP2012510116A JP2012526152A (ja) 2009-05-11 2010-05-11 Ｎ−（２，６−ジメチル−４−モルホリン−４−イル−フェニル）−３，３−ジメチル−ブチルアミドの安定形態
CN2010800321765A CN102459208A (zh) 2009-05-11 2010-05-11 N-(2,6-二甲基-4-吗啉-4-基-苯基)-3,3-二甲基-丁酰胺的稳定形式
IL216148A IL216148A0 (en) 2009-05-11 2011-11-03 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
ZA2011/08112A ZA201108112B (en) 2009-05-11 2011-11-04 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
TNP2011000557A TN2011000557A1 (en) 2009-05-11 2011-11-04 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11
DKPA200900597 2009-05-11

Publications (3)

Publication Number Publication Date
WO2010130260A2 WO2010130260A2 (fr) 2010-11-18
WO2010130260A3 true WO2010130260A3 (fr) 2011-06-16
WO2010130260A9 WO2010130260A9 (fr) 2012-10-18

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2010/050101 WO2010130260A2 (fr) 2009-05-11 2010-05-11 Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide

Country Status (23)

Country Link
EP (1) EP2430008A2 (fr)
JP (1) JP2012526152A (fr)
KR (1) KR20120022934A (fr)
CN (1) CN102459208A (fr)
AR (1) AR076556A1 (fr)
AU (1) AU2010246724B2 (fr)
BR (1) BRPI1013930A2 (fr)
CA (1) CA2761383A1 (fr)
CL (1) CL2011002814A1 (fr)
CO (1) CO6460741A2 (fr)
CR (1) CR20110590A (fr)
DO (1) DOP2011000351A (fr)
EA (1) EA201171381A1 (fr)
GE (1) GEP20146006B (fr)
IL (1) IL216148A0 (fr)
MA (1) MA33351B1 (fr)
MX (1) MX2011011885A (fr)
NZ (1) NZ596738A (fr)
SG (1) SG175968A1 (fr)
TN (1) TN2011000557A1 (fr)
TW (1) TW201041857A (fr)
WO (1) WO2010130260A2 (fr)
ZA (1) ZA201108112B (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087754A1 (fr) * 2004-03-12 2005-09-22 H. Lundbeck A/S Dérivés de morpholine et de thiomorpholine substitués
WO2008024398A2 (fr) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008281112A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of KCNQ potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087754A1 (fr) * 2004-03-12 2005-09-22 H. Lundbeck A/S Dérivés de morpholine et de thiomorpholine substitués
WO2008024398A2 (fr) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/3-540-69178-2_5, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954 *
SAMEER URGAONKAR ET AL: "Palladium/Proazaphosphatrane-Catalyzed Amination of Aryl Halides Possessing a Phenol, Alcohol, Acetanilide, Amide or an Enolizable Ketone Functional Group: Efficacy of Lithium Bis(trimethylsilyl)amide as the Base", ADVANCED SYNTHESIS & CATALYSIS, vol. 346, no. 6, 1 May 2004 (2004-05-01), pages 611 - 616, XP055034677, ISSN: 1615-4150, DOI: 10.1002/adsc.200404005 *

Also Published As

Publication number Publication date
BRPI1013930A2 (pt) 2019-09-24
AR076556A1 (es) 2011-06-22
GEP20146006B (en) 2014-01-10
CN102459208A (zh) 2012-05-16
IL216148A0 (en) 2012-01-31
CR20110590A (es) 2012-02-22
EA201171381A1 (ru) 2012-05-30
TN2011000557A1 (en) 2013-05-24
TW201041857A (en) 2010-12-01
CL2011002814A1 (es) 2012-04-13
CO6460741A2 (es) 2012-06-15
JP2012526152A (ja) 2012-10-25
AU2010246724B2 (en) 2013-03-21
KR20120022934A (ko) 2012-03-12
EP2430008A2 (fr) 2012-03-21
WO2010130260A9 (fr) 2012-10-18
SG175968A1 (en) 2011-12-29
DOP2011000351A (es) 2012-01-31
WO2010130260A2 (fr) 2010-11-18
MA33351B1 (fr) 2012-06-01
AU2010246724A1 (en) 2011-12-08
ZA201108112B (en) 2013-01-30
MX2011011885A (es) 2011-12-06
NZ596738A (en) 2013-04-26
CA2761383A1 (fr) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2009048101A1 (fr) Composé amide
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
WO2009036281A3 (fr) Bortézomib et procédé de production de celui-ci
EP2361902A4 (fr) 4,6-diaminonicotinamide
WO2009012734A3 (fr) Nouveaux sels de bazédoxifène
WO2010015657A3 (fr) Nouveaux alcoxypyrazoles
EP2227690A4 (fr) Plaque de microchambre et son procédé de fabrication
LT2236610T (lt) Patobulintas promotorius ir jo panaudojimas l-lizino gamybos būdui
WO2010039885A3 (fr) Formes cristallines du dexlansoprazole
WO2011018771A3 (fr) Procédé de préparation de chlorhydrate de valganciclovir
MX285136B (es) Metodo de produccion de polieteramina.
ZA201004118B (en) Process for the production of 1,2-propanediol
WO2011134724A3 (fr) Procédé pour la préparation de chlorhydrate de ritodrine
WO2009149344A3 (fr) États solides de base libre d’aliskiren
EG25292A (en) Process for the production of anilines.
WO2009114685A3 (fr) Sels d’o-desméthylvenlafaxine
BRPI0819653A2 (pt) Método para a produção de um composto de tetrapirrol, e, composto de tetrapirrol.
EP2330212A4 (fr) Nouveau composé céramidastine, son procédé de fabrication et son utilisation
WO2010130260A3 (fr) Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide
WO2009027766A3 (fr) Nouvelles formes solides cristallines de la base o-desvenlafaxine
BR112012004523A2 (pt) processo para a preparação de (1s,4r)-2-oxa-3-azabiciclo[2.2.1]hept-5-enos
WO2010004386A3 (fr) Bromhydrate de bupropion amorphe et sa préparation
TWI366559B (en) Process for the production of anilines
WO2011159740A3 (fr) Méthodes de fabrication de métabolites de tétranor-prostaglandine d, j, e, a et f
EP1915380A4 (fr) Procédé de synthèse d oxabispidines n,n´-disubstituées

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080032176.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719726

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2761383

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/011885

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011002814

Country of ref document: CL

Ref document number: 2012510116

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20117026958

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11153611

Country of ref document: CO

Ref document number: 8279/CHENP/2011

Country of ref document: IN

Ref document number: CR2011-000590

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2010246724

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010719726

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 596738

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2010246724

Country of ref document: AU

Date of ref document: 20100511

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12498

Country of ref document: GE

Ref document number: 201171381

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1013930

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 13061

Country of ref document: GE

ENP Entry into the national phase

Ref document number: PI1013930

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111110